CATO 佳途CATO · CNAS + ANAB ISO 17034 双体系认可标准物质生产者CNAS + ANAB ISO 17034 dual-accredited reference material producer
销售顾问Sales contact 卢振明Kaka Lu+86 185 2048 1969kaka@cato-chem.com
Cefditoren Pivoxil

头孢托仑匹酯 杂质对照品Cefditoren Pivoxil Impurities

23 个杂质条目23 impurity entries

本页汇总 头孢托仑匹酯 的 23 个杂质对照品条目。杂质谱是仿制药杂质研究、方法开发与稳定性考察的起点——先锁定品种,再逐条比对结构差异与保留行为。This page collects 23 impurity reference standards of Cefditoren Pivoxil. The impurity profile is the starting point for related-substance method development, forced degradation and stability studies.

批量索取报价 / COABulk quote / COA在全站目录中检索Search the full catalogue

相关研究文献Related literature

以下为 头孢托仑匹酯(Cefditoren Pivoxil)在公开文献中的研究报道(题录信息,来源 PubMed),供方法开发与文献调研参考。Selected peer-reviewed publications on this drug substance — bibliographic records from PubMed.

  1. 分析方法Analytical MethodsIdentification and Characterization of Hydrolytic Degradation Products of Cefditoren Pivoxil using LC and LC-MS/TOF
    Indian journal of pharmaceutical sciences · 2015 · Gawande VT et al.  ·  PMID 25767321  ·  DOI
  2. 分析方法Analytical MethodsDevelopment and validation of the stability-indicating LC-UV method for the determination of Cefditoren pivoxil
    Journal of pharmaceutical analysis · 2012 · Annapurna MM et al.  ·  PMID 29403785  ·  DOI
  3. 分析方法Analytical MethodsApplication of silver nanoparticles to the chemiluminescence determination of cefditoren pivoxil using the luminol-ferricyanide system
    Luminescence : the journal of biological and chemical luminescence · 2015 · Alarfaj NA et al.  ·  PMID 24850667  ·  DOI
  4. 分析方法Analytical MethodsThe use of inverse gas chromatography to assess the acid-base contributions to surface energies of cefditoren pivoxil and methacrylate copolymers and possible links to instability
    International journal of pharmaceutics · 2004 · Ohta M, Buckton G  ·  PMID 15019075  ·  DOI
  5. 分析方法Analytical MethodsDetermination of the changes in surface energetics of cefditoren pivoxil as a consequence of processing induced disorder and equilibration to different relative humidities
    International journal of pharmaceutics · 2004 · Ohta M, Buckton G  ·  PMID 14698579  ·  DOI

头孢托仑匹酯 —— 原料药与杂质对照品Cefditoren Pivoxil — drug substance & impurities

共 24 个条目(含原料药本体)24 items incl. the drug substance
Cefditoren Pivoxil structure
原料药 APIAPI
头孢托仑匹酯Cefditoren Pivoxil
Cefditoren Pivoxil
CAS No.117467-28-4
Chemical FormulaC25H28N6O7S3
Purity>95%询价On request
10mg25mg50mg100mg
Cefditoren Pivoxil Impurity 1 structure
1
头孢托仑匹酯杂质1Cefditoren Pivoxil Impurity 1
Cefditoren Pivoxil Impurity 1
CAS No.138514-32-6
Chemical FormulaC25H28N6O7S3
Purity>95%询价On request
10mg25mg50mg100mg
Cefditoren Pivoxil Impurity 2 structure
2
头孢托仑匹酯杂质2Cefditoren Pivoxil Impurity 2
Cefditoren Pivoxil Impurity 2
CAS No.878002-86-9
Chemical FormulaC25H28N6O7S3
Purity>95%询价On request
10mg25mg50mg100mg
Cefditoren Pivoxil Impurity 3 structure
3
头孢托仑匹酯杂质3Cefditoren Pivoxil Impurity 3
Cefditoren Pivoxil Impurity 3
CAS No.2375345-02-9
Chemical FormulaC13H13N3O3S2
Purity>95%询价On request
10mg25mg50mg100mg
Cefditoren Pivoxil Impurity 5 structure
5
头孢托仑匹酯杂质5Cefditoren Pivoxil Impurity 5
Cefditoren Pivoxil Impurity 5
CAS No.148774-47-4
Chemical FormulaC25H28N6O7S3
Purity>95%询价On request
10mg25mg50mg100mg
Cefditoren Pivoxil Impurity 7 structure
7
头孢托仑匹酯杂质7Cefditoren Pivoxil Impurity 7
Cefditoren Pivoxil Impurity 7
CAS No.878002-85-8
Chemical FormulaC51H56N12O14S6
Purity>95%询价On request
10mg25mg50mg100mg
Cefditoren Pivoxil Impurity 9 structure
9
头孢托仑匹酯杂质9Cefditoren Pivoxil Impurity 9
Cefditoren Pivoxil Impurity 9
CAS No.166374-44-3
Chemical FormulaC13H13N3O3S2
Purity>95%询价On request
10mg25mg50mg100mg
Cefditoren Pivoxil Impurity 11 structure
11
头孢托仑匹酯杂质11Cefditoren Pivoxil Impurity 11
Cefditoren Pivoxil Impurity 11
CAS No.2762536-15-0
Chemical FormulaC27H32N6O8S3
Purity>95%询价On request
10mg25mg50mg100mg
Cefditoren Pivoxil Impurity 12 structure
12
头孢托仑匹酯杂质12Cefditoren Pivoxil Impurity 12
Cefditoren Pivoxil Impurity 12
CAS No.878002-84-7
Chemical FormulaC30H36N6O8S3
Purity>95%询价On request
10mg25mg50mg100mg
Cefditoren Pivoxil Impurity 15 structure
15
头孢托仑匹酯杂质15Cefditoren Pivoxil Impurity 15
Cefditoren Pivoxil Impurity 15
CAS No.104146-14-7
Chemical FormulaC19H18N6O5S3
Purity>95%询价On request
10mg25mg50mg100mg
Cefditoren Pivoxil Impurity 18 structure
18
头孢托仑匹酯杂质18Cefditoren Pivoxil Impurity 18
Cefditoren Pivoxil Impurity 18
CAS No.104145-87-1
Chemical FormulaC25H28N6O7S3
Purity>95%询价On request
10mg25mg50mg100mg
Cefditoren Pivoxil Impurity 19 (N-methoxybenzyl Cefditoren Pivoxil) structure
19
头孢托仑匹酯杂质19 (N-甲氧基苄基头孢妥仑匹酯)Cefditoren Pivoxil Impurity 19 (N-methoxybenzyl Cefditoren Pivoxil)
Cefditoren Pivoxil Impurity 19 (N-methoxybenzyl Cefditoren Pivoxil)
CAS No.3139102-62-5
Chemical FormulaC33H36N6O8S3
Purity>95%询价On request
10mg25mg50mg100mg
Cefditoren Pivoxil Impurity 21 structure
21
头孢托仑匹酯杂质21Cefditoren Pivoxil Impurity 21
Cefditoren Pivoxil Impurity 21
CAS No.155723-02-7
Chemical FormulaC13H13N3O3S2
Purity>95%询价On request
10mg25mg50mg100mg
Cefditoren Pivoxil Impurity 22 Monomer structure
22
头孢托仑匹酯杂质22 单体Cefditoren Pivoxil Impurity 22 Monomer
Cefditoren Pivoxil Impurity 22 Monomer
CAS No.104145-95-1
Chemical FormulaC19H18N6O5S3
Purity>95%询价On request
10mg25mg50mg100mg
Cefditoren Pivoxil Impurity 22 structure
22
头孢托仑匹酯杂质22Cefditoren Pivoxil Impurity 22
Cefditoren Pivoxil Impurity 22
CAS No.104146-53-4
Chemical FormulaC19H17N6O5S3-·Na+
Purity>95%询价On request
10mg25mg50mg100mg
Cefditoren Pivoxil Impurity 22 Nitrate structure
22
头孢托仑匹酯杂质22硝酸盐Cefditoren Pivoxil Impurity 22 Nitrate
Cefditoren Pivoxil Impurity 22 Nitrate
CAS No.352465-65-7
Chemical FormulaC19H18N6O5S3·n(HNO3)
Purity>95%询价On request
10mg25mg50mg100mg
Cefditoren Pivoxil Impurity 23 structure
23
头孢托仑匹酯杂质23Cefditoren Pivoxil Impurity 23
Cefditoren Pivoxil Impurity 23
CAS No.2254227-50-2
Chemical FormulaC26H30N6O8S3
Purity>95%询价On request
10mg25mg50mg100mg
Cefditoren Pivoxil Impurity 24 structure
24
头孢托仑匹酯杂质24Cefditoren Pivoxil Impurity 24
Cefditoren Pivoxil Impurity 24
CAS No.145904-68-3
Chemical FormulaC19H18N6O5S3
Purity>95%询价On request
10mg25mg50mg100mg
Cefditoren Pivoxil Impurity 29 structure
29
头孢托仑匹酯杂质29Cefditoren Pivoxil Impurity 29
Cefditoren Pivoxil Impurity 29
CAS No.1205564-87-9
Chemical FormulaC19H18N6O5S3
Purity>95%询价On request
10mg25mg50mg100mg
Cefditoren Pivoxil Impurity 30 structure
30
头孢托仑匹酯杂质30Cefditoren Pivoxil Impurity 30
Cefditoren Pivoxil Impurity 30
CAS No.2630913-85-6
Chemical FormulaC25H28N6O7S3
Purity>95%询价On request
10mg25mg50mg100mg
Cefditoren Pivoxil Impurity 34 structure
34
头孢托仑匹酯杂质34Cefditoren Pivoxil Impurity 34
Cefditoren Pivoxil Impurity 34
CAS No.2410655-60-4
Chemical FormulaC50H56N12O14S6
Purity>95%询价On request
10mg25mg50mg100mg
Cefditoren Pivoxil Impurity 38 structure
38
头孢托仑匹酯杂质38Cefditoren Pivoxil Impurity 38
Cefditoren Pivoxil Impurity 38
CAS No.2409806-43-3
Chemical FormulaC25H30N6O8S3
Purity>95%询价On request
10mg25mg50mg100mg
Cefditoren Pivoxil Impurity 41 structure
41
头孢托仑匹酯杂质41Cefditoren Pivoxil Impurity 41
Cefditoren Pivoxil Impurity 41
CAS No.2767466-38-4
Chemical FormulaC25H28N6O8S3
Purity>95%询价On request
10mg25mg50mg100mg
Cefditoren Pivoxil Impurity 52 structure
52
头孢托仑匹酯杂质52Cefditoren Pivoxil Impurity 52
Cefditoren Pivoxil Impurity 52
CAS No.1385261-52-8
Chemical FormulaC19H18N6O5S3
Purity>95%询价On request
10mg25mg50mg100mg

结构式清晰度以随货 COA 与厂家图谱为准;目录之外的杂质可按需定制合成或调取。Structural confirmation is governed by the COA and manufacturer spectra. Impurities outside this list can be custom-synthesised or sourced on request.

Literature & synthesis

头孢托仑匹酯 —— 研究文献与合成路线Cefditoren Pivoxil — literature & synthetic routes

以下题录由公开学术数据库按品种名检索汇总,供 头孢托仑匹酯 的杂质谱研究、分析方法开发与工艺路线选择参考。文献题名与专利标题均可点击查看原文,版权归原作者与出版方所有。Citations below are aggregated from public scholarly databases by drug-substance name, for reference in impurity profiling, analytical method development and route selection for Cefditoren Pivoxil. Titles link to the original records; copyright remains with the authors and publishers.

杂质与降解研究文献Impurity & degradation studies

  1. Identification and Characterization of Hydrolytic Degradation Products of Cefditoren Pivoxil using LC and LC-MS/TOF
    Gawande VT, Bothara KG, Singh A, et al. · Indian journal of pharmaceutical sciences · 2015 · 被引 1cited 1

合成与制备工艺专利Synthesis & process patents

  1. Method for preparing cefditoren pivoxil
    WANBIN ZHANG, DELONG LIU · 公开号 CN101560216CN101560216 · 2009
  2. Cefditoren pivoxil dry suspensoid and its preparing process
    LOU JIANBO REN · 公开号 CN1843361CN1843361 · 2006
  3. Stable solid preparation containing amorphous cefditoren pivoxil and preparation method thereof
    — · 公开号 CN101103965CN101103965 · 2008
  4. CEFDITOREN PIVOXIL PHARMACEUTICAL PREPARATION EXCELLENT IN DISSOLUTION PROPERTY
    KANAI TATSUO, KOSUGI ATSUSHI · 公开号 JP2005162696JP2005162696 · 2005
  5. CEFDITOREN PIVOXIL MESITYLENE SULFONIC ACID SALT AND METHOD FOR PREPARING THE SAME
    CHOI YEONG JAE, KANG SEOK WON, KIM MUN SIK, KWON JI UNG, et al. · 公开号 KR20040035196KR20040035196 · 2004

题录与链接来自公开数据库 Europe PMC(含 PubMed 与全球专利题录)与 WIPO PatentScope,本站仅提供索引,不转载正文;如链接失效请以数据库检索为准。Citations are indexed from public databases (Europe PMC incl. PubMed and patent records, WIPO PatentScope); we provide links only and do not reproduce full text.

For formulation & analytical R&D

头孢托仑匹酯 杂质谱研究要点Cefditoren Pivoxil — impurity profiling notes

下面这些是拿到 头孢托仑匹酯 的 24 个杂质条目之后,仿制药研发最常遇到的几件事。先把杂质的来源分清,再决定要不要买对照品、买哪几个。Once you have the 24 impurity entries for Cefditoren Pivoxil, these are the questions that come up most in generic development. Classify the source of each impurity first, then decide which reference standards you actually need.

01工艺杂质Process impurities

起始物料、中间体、副产物、催化剂与溶剂残留。多来自合成路线本身,应在工艺开发阶段用加标试验定位。Starting materials, intermediates, by-products, catalysts and residual solvents — traced back to the synthetic route and located with spiking studies during process development.

02降解杂质Degradation impurities

水解、氧化、光解、高温高湿与聚合产物。需通过强制降解试验识别,并确认方法具备稳定性指示能力。Hydrolytic, oxidative, photolytic, thermal and polymeric degradants — identified through forced degradation, with the method proven stability-indicating.

03药典杂质Pharmacopoeial impurities

EP/USP 已收载并有官方编号的杂质(如 EP Impurity A、USP Related Compound B)。申报时通常需逐项对照。Impurities already monographed with official designations (e.g. EP Impurity A, USP Related Compound B), normally compared item by item during filing.

04基因毒性杂质Genotoxic impurities

含警示结构、需按 ICH M7 进行危害评估与限度推导(TTC 1.5 µg/日)。该类杂质必须用对照品准确控制。Structurally alerting compounds requiring ICH M7 hazard assessment and limit derivation (TTC 1.5 µg/day); these must be controlled with an authentic reference standard.

05同位素标记物Isotopically labelled standards

氘代、¹³C、¹⁵N 标记的同类物,主要用作 LC-MS/MS 生物分析的内标,抵消基质效应与回收率波动。Deuterated, ¹³C- and ¹⁵N-labelled analogues used as internal standards in LC-MS/MS bioanalysis to compensate matrix effects and recovery variation.

06代谢与转化产物Metabolites & conversion products

体内代谢物、强制降解转化物与工艺中间态,常见于杂质谱比对与稳定性考察中。In-vivo metabolites, forced-degradation products and process intermediates encountered in impurity profiling and stability studies.

方法开发与对照品使用建议Method development and standards usage

先定分离,再谈定量Resolution first, then quantification

主成分与相邻杂质峰分离度应 ≥1.5;用杂质对照品确定相对保留时间与相对响应因子,避免用自身对照法掩盖响应差异。Target baseline resolution ≥1.5 between the main component and adjacent impurities; establish relative retention and relative response factors with authentic impurity standards rather than relying on self-comparison.

校正因子不可忽略Never ignore response factors

紫外吸收差异大的杂质必须校正,否则定量结果系统性偏低或偏高。EP/USP 已给出校正因子的按药典执行。Impurities with markedly different UV response need correction, otherwise results are systematically biased. Where EP/USP publish a correction factor, follow the monograph.

强制降解要做全Run the full forced-degradation panel

建议覆盖酸、碱、氧化(H₂O₂)、光照(ICH Q1B)、高温高湿;主峰纯度用二极管阵列或质谱确认。Cover acid, base, peroxide oxidation, photostability (ICH Q1B) and heat/humidity; confirm peak purity by DAD or MS.

定义报告阈值Set reporting and identification thresholds

按 ICH Q3A/Q3B 设定报告阈值、鉴定阈值与界定阈值,避免为无意义的峰投入过多工作量。Apply ICH Q3A/Q3B reporting, identification and qualification thresholds so effort is not spent on insignificant peaks.

标准品储存有讲究Store standards properly

杂质对照品多建议 −20 ℃ 避光、干燥、密封保存;溶液现配现用,并记录开瓶与配制日期。Most impurity standards should be stored at −20 °C, protected from light and moisture; prepare solutions fresh and record opening and preparation dates.

用结构式先做初判Start from the structure

先比对杂质与主成分的结构差异,可预判其保留行为、紫外响应与可能的降解路径,能显著减少试错。Comparing the impurity structure with the parent drug predicts retention behaviour, UV response and probable degradation routes, cutting trial and error.

以上为通行的杂质研究实践提示,不针对具体品种给出结论。实际限度、校正因子与色谱条件请以 EP/USP 各论及你们的验证数据为准。需要某个杂质的结构确证资料、COA 或定制合成,可直接联系我们。The above are general impurity-profiling notes and are not conclusions about this specific drug substance. Actual limits, correction factors and chromatographic conditions follow the EP/USP monograph and your own validation data. Contact us for structural confirmation data, COAs or custom synthesis.
索取杂质谱报价 / COARequest a quote / COA← 查看其它品种← Other drug substances